Retacrit will be priced 57.1% below the Wholesale Acquisition Cost (WAC) of Procrit and 33.5% below the WAC of Epogen, at $11.03 per 1000 Units/mL. In addition, Retacrit is indicated for the reduction ...
Here are three things to know. 1. Like Amgen’s Epogen and Johnson & Johnson’s Procrit, Retacrit may now be used to treat anemia linked to chronic kidney disease, chemotherapy or the use of zidovudine ...
The US Food and Drug Administration (FDA) has approved the first biosimilar erythropoiesis-stimulating agent. The reference product is epoetin alfa (Epogen/Procrit, Amgen). The new biosimilar is ...
EXTON, Pa., July 31, 2018 /PRNewswire/ -- Plagued by regulatory delays, the FDA finally granted approval for Retacrit in May 2018, making it the first biosimilar erythropoietin-stimulating agent (ESA) ...
After experiencing slow uptake for its first biosim launch, Pfizer isn’t giving up on the budding field. On Wednesday, the drugmaker introduced its third biosim, and second in two months, launching ...
CHICAGO, Dec 19 (Reuters) - Hospira Inc said on Wednesday it won European approval to sell Retacrit, also known as epoetin zeta, a generic version of erythropoietin, as a treatment for anemia ...
Decisions by major central banks this week brought the end of pandemic-era monetary policy into closer view, but also highlighted how long the road back to "normal" will be as officials now probe for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback